Proteomic characterization of atopic dermatitis blood from infancy to adulthood - 14/04/23
, Emma Guttman-Yassky, MD, PhD a, c, ⁎ Abstract |
Background |
Patients with atopic dermatitis (AD) have systemic biomarker dysregulation that differs by age group; however, the proteomic characteristics of these age-based changes are unknown.
Objective |
To profile blood proteins of patients with AD across different age groups versus age-appropriate controls.
Methods |
Using the Olink high-throughput proteomic platform, we profiled 375 serum proteins of 20 infants (age, 0-5 years), 39 children (age, 6-11 years), 21 adolescents (age, 12-17 years), and 20 adults (age, ≥18 years) with moderate-to-severe AD and 83 age-appropriate controls.
Results |
Each group presented a distinct systemic proteomic signature. Th2-related proteins were increased in infant AD and further intensified with age through adolescence and adulthood (interleukin 4/CCL13/CCL17). In contrast, Th1 axis down-regulation was detected in infants with AD and gradually reversed to increased Th1 products (interferon γ/CXCL9/CXCL10/CCL2) in patients with AD from childhood to adulthood. Despite their short disease duration, infants already had evidence of systemic inflammation, with significant upregulation of innate immunity (interleukin 17C/ interleukin-1RN), T-cell activation/migration (CCL19), Th2 (CCL13/CCL17), and Th17 (PI3) proteins. Adults with AD present unique upregulation of cardiovascular proteins related to coagulation and diabetes.
Limitations |
Cross-sectional observational study with a single time point.
Conclusion |
Systemic immune signatures of AD are age-specific beyond the shared Th2 immune activation. These data advocate for precision medicine approaches based on age-specific AD profiles.
Le texte complet de cet article est disponible en PDF.Key words : atopic dermatitis, Olink, pediatric, proteomic
Abbreviations used : AD, DEP, FCH, FDR, IgE, IL, SCORAD
Plan
| Drs Del Duca, Renert-Yuval, and Pavel contributed equally to this article. |
|
| Drs Amy S. Paller and Emma Guttman-Yassky contributed equally to this article. |
|
| Funding sources: Supported by a research grant from the LEO Foundation. |
|
| YRY was supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through Rockefeller University, Grant #UL1TR001866. RL received partial salary support from a National Psoriasis Foundation fellowship grant. Tissue and blood collection was supported by Northwestern University Skin Biology and Diseases Resource-based Center, NIAMS #P30AR075049. |
|
| IRB approved status: Reviewed and approved by Mount Sinai Hospital, Northwestern University, and Lurie Children’s Hospital IRBs. |
|
| Reprints not available from the authors. |
Vol 88 - N° 5
P. 1083-1093 - mai 2023 Retour au numéro
Article précédent
- Human monkeypox outbreak: Epidemiological data and therapeutic potential of topical cidofovir in a prospective cohort study
- Tristán Gabriel Sobral-Costas, Rafael Escudero-Tornero, Guillermo Servera-Negre, Jose I. Bernardino, Almudena Gutiérrez Arroyo, Marta Díaz-Menéndez, Jose Manuel Busto-Leis, Patricia Roces Álvarez, Pedro Herranz Pinto, Elena Sendagorta Cudos
- Baseline skin cytokine profiles determined by RNA in situ hybridization correlate with response to dupilumab in patients with eczematous dermatitis
- Katelyn Singh, Kailyn Valido, Madisen Swallow, Kevin O. Okifo, Alice Wang, Jeffrey M. Cohen, William Damsky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?